The FDA Law Blog

JANUARY 18, 2024

Houck — In August 2023 the Food and Drug Administration (“FDA”) and Health and Human Services (“HHS”) recommended that the Drug Enforcement Administration (“DEA”) reschedule marijuana from schedule I under the federal Controlled Substances Act (“CSA”) to schedule III. chemotherapy-induced), pain, and post-traumatic stress disorder.

FDA 69

FDA Controlled Substances Chemotherapy Compounding 69

The FDA Law Blog

FEBRUARY 11, 2024

Letter 3: Top Ten Reasons for Descheduling Cannabis Altogether From: Democratic Senators Date: January 29, 2024 Twelve Democratic senators signed Letter 3. January 29, 2024). Letter to DEA Administrator Anne Milgram, from Phil Weiser, et al., (Jan.

Controlled Substances 59

Controlled Substances Chemotherapy Compounding FDA 59

The FDA Law Blog

MAY 5, 2024

Houck — The Associated Press reported on Tuesday following confirmation by five anonymous individuals with knowledge that the Drug Enforcement Administration (“DEA”) is moving to reschedule marijuana from schedule I to the less stringently controlled schedule III. treaty obligations in rescheduling. 21 U.S.C. § 812(b)(1). at 63-64.

Controlled Substances 91

Controlled Substances FDA Chemotherapy Dosage 91